Literature DB >> 22958901

Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts.

Alexander G Bick1, Jason Flannick, Kaoru Ito, Susan Cheng, Ramachandran S Vasan, Michael G Parfenov, Daniel S Herman, Steven R DePalma, Namrata Gupta, Stacey B Gabriel, Birgit H Funke, Heidi L Rehm, Emelia J Benjamin, Jayashri Aragam, Herman A Taylor, Ervin R Fox, Christopher Newton-Cheh, Sekar Kathiresan, Christopher J O'Donnell, James G Wilson, David M Altshuler, Joel N Hirschhorn, J G Seidman, Christine Seidman.   

Abstract

Rare sarcomere protein variants cause dominant hypertrophic and dilated cardiomyopathies. To evaluate whether allelic variants in eight sarcomere genes are associated with cardiac morphology and function in the community, we sequenced 3,600 individuals from the Framingham Heart Study (FHS) and Jackson Heart Study (JHS) cohorts. Out of the total, 11.2% of individuals had one or more rare nonsynonymous sarcomere variants. The prevalence of likely pathogenic sarcomere variants was 0.6%, twice the previous estimates; however, only four of the 22 individuals had clinical manifestations of hypertrophic cardiomyopathy. Rare sarcomere variants were associated with an increased risk for adverse cardiovascular events (hazard ratio: 2.3) in the FHS cohort, suggesting that cardiovascular risk assessment in the general population can benefit from rare variant analysis.
Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22958901      PMCID: PMC3511985          DOI: 10.1016/j.ajhg.2012.07.017

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension.

Authors:  D W Brown; W H Giles; J B Croft
Journal:  Am Heart J       Date:  2000-12       Impact factor: 4.749

2.  Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation.

Authors:  R S Vasan; M G Larson; D Levy; J C Evans; E J Benjamin
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

3.  Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study.

Authors:  Giovanni de Simone; Vittorio Palmieri; Jonathan N Bella; Aldo Celentano; Yuling Hong; Albert Oberman; Dalane W Kitzman; Paul N Hopkins; Donna K Arnett; Richard B Devereux
Journal:  J Hypertens       Date:  2002-02       Impact factor: 4.844

4.  The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation.

Authors:  D Georgakopoulos; M E Christe; M Giewat; C M Seidman; J G Seidman; D A Kass
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

5.  Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities.

Authors:  B J Maron; R Mathenge; S A Casey; L C Poliac; T F Longe
Journal:  J Am Coll Cardiol       Date:  1999-05       Impact factor: 24.094

6.  A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study.

Authors:  W B Kannel; R D Abbott
Journal:  Am Heart J       Date:  1986-02       Impact factor: 4.749

7.  The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study.

Authors:  M S Lauer; K M Anderson; W B Kannel; D Levy
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

Review 8.  Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables.

Authors:  R B Devereux; T G Pickering; M H Alderman; S Chien; J S Borer; J H Laragh
Journal:  Hypertension       Date:  1987-02       Impact factor: 10.190

9.  Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings.

Authors:  P N Casale; R B Devereux; D R Alonso; E Campo; P Kligfield
Journal:  Circulation       Date:  1987-03       Impact factor: 29.690

Review 10.  Genetics of hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Stephen Chang; Jonathan G Seidman; Christine E Seidman
Journal:  Curr Opin Cardiol       Date:  2010-05       Impact factor: 2.161

View more
  60 in total

1.  Phenotypic extremes in rare variant study designs.

Authors:  Gina M Peloso; Daniel J Rader; Stacey Gabriel; Sekar Kathiresan; Mark J Daly; Benjamin M Neale
Journal:  Eur J Hum Genet       Date:  2015-09-09       Impact factor: 4.246

2.  Commercial clinical genetic sequencing panels for evaluating patients with familial disease--are they ready for prime time?

Authors:  Arthur Feldman
Journal:  Clin Transl Sci       Date:  2013-05-15       Impact factor: 4.689

Review 3.  Closing the 'phenotype gap' in precision medicine: improving what we measure to understand complex disease mechanisms.

Authors:  Calum A MacRae
Journal:  Mamm Genome       Date:  2019-08-19       Impact factor: 2.957

Review 4.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 5.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

6.  Poor prognosis of rare sarcomeric gene variants in patients with dilated cardiomyopathy.

Authors:  Marco Merlo; Gianfranco Sinagra; Elisa Carniel; Dobromir Slavov; Xiao Zhu; Giulia Barbati; Anita Spezzacatene; Federica Ramani; Ernesto Salcedo; Andrea Di Lenarda; Luisa Mestroni; Matthew R G Taylor
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

7.  [Individualized stem cell therapy].

Authors:  W-H Zimmermann
Journal:  Herz       Date:  2014-03       Impact factor: 1.443

8.  Causality in genetics: the gradient of genetic effects and back to Koch's postulates of causality.

Authors:  Ali J Marian
Journal:  Circ Res       Date:  2014-01-17       Impact factor: 17.367

Review 9.  Mendelian forms of structural cardiovascular disease.

Authors:  Calum A MacRae
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

10.  Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes.

Authors:  Jason Flannick; Nicola L Beer; Alexander G Bick; Vineeta Agarwala; Janne Molnes; Namrata Gupta; Noël P Burtt; Jose C Florez; James B Meigs; Herman Taylor; Valeriya Lyssenko; Henrik Irgens; Ervin Fox; Frank Burslem; Stefan Johansson; M Julia Brosnan; Jeff K Trimmer; Christopher Newton-Cheh; Tiinamaija Tuomi; Anders Molven; James G Wilson; Christopher J O'Donnell; Sekar Kathiresan; Joel N Hirschhorn; Pål R Njølstad; Tim Rolph; J G Seidman; Stacey Gabriel; David R Cox; Christine E Seidman; Leif Groop; David Altshuler
Journal:  Nat Genet       Date:  2013-10-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.